All AbMole products are for research use only, cannot be used for human consumption.
TGX-221 is a potent, selective, and cell permeable inhibitor of PI3K p110β. Inhibition appears to occur at the ATP binding site based on the observed increase in IC50 from 5 to ~50 nM at ATP concentrations of 50 µM and 1 mM, respectively. TGX-221 inhibits PtdIns-(3,4)-P2 production in platelets with an IC50 of 50 nM. Selective inhibition of PI3K p110β results in defective platelet thrombus formation and defines PI3K as a target for antithrombotic therapy.
Cell Commun Signal. 2022 Jul 7;20(1):102.
Circular dorsal ruffles disturb the growth factor-induced PI3K-AKT pathway in hepatocellular carcinoma Hep3B cells
TGX-221 purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | BT-474 and HCT-116 cell lines |
Preparation method | For measurement of proliferation, cells were seeded in triplicate at 2×103 cells/well in 96-well culture plates and incubated overnight to allow cell attachment. The cells were incubated with the TGX221-loaded PHA nanoparticles, empty PHA nanoparticles, or free TGX221 for 24, 48, and 72 h. At designated time intervals, cells were quantified by a crystal violet staining-based colorimetric assay (Kueng et al. 1989). Briefly, cells were fixed by addition of 100 μl of 2.5% glutaraldehyde solution andincubated at room temperature for 30 min. Plates were washed three times by submersion in PBS solution. Plates were air-dried and stained by addition of 100 μl of 0.1% solution of crystal violet dissolved in deionized water and incubated for 20 min at room temperature, excess dye was removed by extensive washing with deionized water, and plates were air-dried prior to bound dye solubilization in 100 μ1 of 10% acetic acid. The optical density of dye extracts was measured directly in plates using a microplate reader (Bio-Rad Laboratories, Inc., UK) at 570 nm. |
Concentrations | 0.2, 2 and 20 μ M |
Incubation time | 24, 48, and 72 h |
Animal Experiment | |
---|---|
Animal models | prostate cancer LAPC-4, LNCaP, 22RV1 and C4-2 cellsxenograft tumor in nude mice |
Formulation | dissolved in polypropylene glycol (PPG) |
Dosages | 100 mg/kg twice a week for 3 weeks |
Administration | tail vein injection |
Molecular Weight | 364.4 |
Formula | C21H24N4O2 |
CAS Number | 663619-89-4 |
Solubility (25°C) | DMSO 18 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Related PI3K Products |
---|
PI3Kγ inhibitor AZ2
PI3Kγ inhibitor AZ2 is a highly selective PI3Kγ inhibitor (The pIC50 value for PI3Kγ is 9.3). |
NIBR-17
NIBR-17 is a pan-class I PI3K inhibitor with suitable pharmacokinetic properties and inhibits tumor growth. |
RV-1729
RV-1729 is an inhibitor of the phosphatidylinositol 3-kinase-δ (PI3Kδ). |
Vulolisib
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC50 values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. |
Vps34-IN-4
Vps34-IN-4 is a potent, selective, and orally active inhibitor of VPS34. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.